Hubbry Logo
SynthesSynthesMain
Open search
Synthes
Community hub
Synthes
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Synthes
Synthes
Synthes
View on Wikipedia
from Wikipedia

Synthes Holding AG (formerly Synthes-Stratec) is a multinational medical device manufacturer based in Solothurn, Switzerland and West Chester, Pennsylvania, United States. It is the world's largest maker of implants to mend bone fractures,[2] and also produces surgical power tools and advanced biomaterials.

Key Information

In June 2012 Synthes was sold by its chairman, former CEO and largest shareholder Hansjörg Wyss to Johnson & Johnson for $20.2 billion.[3] The company is part of Johnson & Johnson MedTech business segment.[4]

History

[edit]

Synthes was originally established in 1960 as a trademark of the Swiss non-profit institute Arbeitsgemeinschaft für Osteosynthesefragen (English: Association for the Study of Internal Fixation, AO/ASIF),[5]

The Synthes trademark was applied to internal fixation implants produced under license by its industrial partners, Straumann Group and Mathys Medizinaltechnik.[6] In 1975, the company Synthes (internal fixation implants) was spun off from AO/ASIF and Straumann who focused thereafter on tooth implants.[7] In the same year, Synthes USA, a firm founded by Harvard graduate Hansjörg Wyss, became the third company to form an alliance with AO/ASIF. Throughout the decade, Straumann and Mathys expanded their coverage around the rest of the world.[8] Because of its affiliation with AO/ASIF, which is in involved in mandatory training for many European orthopedic surgeons, healthcare practitioners are more likely to have brand loyalty to Synthes products.[9]

In 1990 Straumann spun off its implant business into a separate privately owned company, Stratec Medical.[10] Stratec partially listed its shares on the SWX Swiss Exchange through an initial public offering six years later, while Synthes USA and Mathys remained in private hands.[11]

Three years later, however, Stratec and Synthes USA merged to form a new publicly traded company named Synthes-Stratec. After the merger Hansjörg Wyss became, and remained (until the sale to Johnson & Johnson) the majority shareholder of the enlarged company.[12]

The third of the original AO/ASIF partner companies, Mathys, sold its osteosynthesis department to Synthes-Stratec in 2004,[13] although the firm's German division was divested to satisfy competition authorities.[14] The company subsequently dropped the "-Stratec" suffix to become simply Synthes. The company's shares were added to the benchmark Swiss Market Index for the first time in September 2004.[15]

In 2006 the company acquired the rights to the Synthes brand name and most of the related intellectual property, including patents, from the AO/ASIF foundation for around CHF1 billion.[16] AO also acquired a stake in Synthes. The two organisations continue to collaborate on relevant issues.

In October 2010, Synthes and its subsidiary Norian both pleaded guilty to crimes relating to illegally implanting bone cement without FDA approval. Norian will admit to a felony charge of conspiracy to impede FDA functions and pay a $23 million fine. Synthes will then divest Norian.[17]

In November 2010, Synthes acquired USA based privately owned surgical tools maker The Anspach Effort, Inc; the purchase price was not disclosed.[18]

On April 27, 2011, Synthes and Johnson and Johnson DePuy agreed to a merger deal. The merger created the world's largest orthopedic corporation.[19]

On June 13, 2012 Johnson & Johnson announced the acquisition of Synthes for $19.7 billion.[20] The merger led to jobs losses for some subsidiary groups. In Italy, the headquarters were moved from Milan to Rome.

Products

[edit]

The company's product offering spans six divisions, of which four produce implants and related instruments for the treatment of physical trauma, spinal injuries and CMF (craniomaxillofacial) trauma, as well as for osteotomy in animals such as horses and dogs. Synthes' other business segments are the production of surgical power tools and biomaterials used to fill bone defects.

Norian XR scandal

[edit]

In 2009 the U.S. attorney in Philadelphia accused the company of illegally promoting a bone void filler for unapproved uses, running unauthorized clinical trials, and failing to properly report deaths and adverse events related to the product.[21] Between 2002 and 2004, Synthes attempted to promote new uses for a product called Norian XR, a calcium phosphate bone void filler mixed with barium sulfate. The Food and Drug Administration explicitly told Synthes not to promote Norian for certain spine surgeries, but the company pushed forward anyway. At least five patients who had Norian injected into their spines died on the operating-room table.[22]

In 2009 Synthes announced a settlement with the state of New Jersey over concerns that clinical investigators did not disclose their financial interests. In November 2009 Synthes pleaded guilty to allegations of shipping “adulterated and misbranded” products as part of unlawful clinical trials.[23]

The indictment charges Synthes Inc. with a total of 52 felony counts: conspiracy to impair and impede the lawful functions of the FDA and to commit crimes against the US; 7 counts of making false statements in connection with an FDA inspection; and 44 counts of shipping adulterated and misbranded Norian XR in interstate commerce with intent to defraud.

The parent company, Synthes, was charged with 44 misdemeanor counts of shipping adulterated and misbranded Norian XR in interstate commerce, and the four executives, Michael D. Huggins, Thomas B. Higgins, Richard E. Bohner and John J. Walsh, were each charged with one strict liability misdemeanor offense. Synthes Inc. acquired N Spine Inc. in 2007.[22]

From May 2002 until fall 2004 Norian conspired with others, including Synthes and the four named executives, to conduct unauthorized clinical trials of Synthes's medical devices, Norian XR and Norian SRS, in surgeries to treat vertebral compression fractures of the spine (VCFs), a painful condition commonly suffered by elderly individuals.[22]

These surgeries were allegedly performed despite a warning on the FDA-cleared label for Norian XR against this use, and in the face of serious medical concerns about the safety of the devices when used in the spine.

According to the indictment, before the marketing program began, pilot studies showed the company that the bone cement reacted chemically with human blood in a test tube to cause blood clots. The research also showed, in a pig, that leakage of small amounts of Norian XR from the spine into the blood caused clots, which become lodged in the lungs. Notwithstanding this knowledge, the company allegedly proceeded to market the product for VCFs without putting it through FDA-required testing. The company, it is alleged, did not stop marketing the product until after a third patient had died on the operating table.[22][24]

In late 2011, all four executives received prison sentences ranging from five to nine months.[22][25]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Synthes

View on Grokipedia
from Grokipedia
Synthes Holding AG is a Swiss-based multinational manufacturer founded in 1960, specializing in the development, production, and distribution of implants, instruments, and biomaterials for surgical fixation of bone and orthopedic procedures. The company originated from innovations stemming from the AO Foundation's research into osteosynthesis techniques and grew to become the world's largest maker of fixation implants. In 2012, acquired Synthes for $19.7 billion, integrating it with DePuy to form , which offers comprehensive orthopedic solutions across joint reconstruction, trauma, spine, craniomaxillofacial, and specialties. DePuy Synthes has been recognized for advancing surgical technologies, including pioneering treatments for joint reconstruction and spinal trauma, contributing to improved patient outcomes in orthopedic care. However, Synthes faced significant controversy in the early over the off-label promotion of its XR for spinal vertebral fractures, a use not approved by the FDA, which led to at least five patient deaths, federal indictments of the company and four executives, criminal convictions, and subsequent civil settlements. As of October 2025, announced plans to separate its orthopaedics , positioning as a standalone entity focused exclusively on orthopedic innovations.

History

Founding and Early Innovations

Synthes traces its origins to the Arbeitsgemeinschaft für Osteosynthesefragen (AO/ASIF), a formed in 1958 by surgeons including Maurice E. Müller, Martin Allgöwer, , Hans Willenegger, and Walter Bandi to develop and standardize methods for treating with metal implants. The AO/ASIF emphasized empirical testing in the for Experimental Surgery established in in 1959, prioritizing absolute stability through compression plating and screw fixation to enable anatomic reduction, preserve vascularity, and facilitate early functional rehabilitation over traditional non-operative approaches like prolonged casting. This biomechanical rationale, validated through animal models and clinical outcomes, shifted fracture care toward operative precision. In December 1960, Synthes AG Chur was founded in specifically to manufacture and commercialize AO/ASIF-designed instruments and implants, safeguarding the efforts of instrument maker Robert Mathys and the association from production risks while ensuring and distribution. Initial products included the first comprehensive AO sets for plate fixation, featuring self-compressing plates and cancellous bone screws designed for interfragmentary compression and load-sharing with healing bone. Early breakthroughs encompassed the introduction of 4.5 mm malleolar screws in the early , optimized for fixation of ankle fractures with their partially threaded design to achieve compression without excessive on fragile cortical . By the 1970s, Synthes had developed modular, standardized instrumentation trays that streamlined surgical workflows, incorporating torque-limiting devices and precise drill guides to minimize complications like implant loosening or malreduction, thereby establishing the technical foundation for reproducible osteosynthesis. These innovations were codified in the 1970 Manual of Internal Fixation, which detailed AO/ASIF protocols based on prospective data showing reduced non-union rates compared to earlier methods.

Expansion and Market Leadership

Synthes expanded into the market in the , with Synthes USA established in 1975 through an alliance with the AO/ foundation, marking a pivotal step in its global outreach. This entry facilitated broader distribution of its orthopedic implants and instruments, leveraging the AO principles of anatomical reduction and stable fixation. By the late , the company had established manufacturing operations in , supporting production for the North American market and enabling scalable growth. The firm's international expansion during the to involved building a multinational presence, with headquarters in , , and subsidiaries across , , and beyond, driven by demand for advanced trauma and reconstructive devices. This period saw substantial R&D investment focused on engineering-driven innovations, including self-tapping screws that improved insertion efficiency and reduced surgical time, as well as locking plates that provided enhanced stability without excessive compression on bone tissue. Modular systems, such as those for hand and foot reconstruction, further exemplified this approach by allowing customizable assemblies for complex fractures, promoting minimally invasive techniques rooted in biomechanical principles. In July 1999, Synthes acquired Corporation for approximately $50 million, integrating bioresorbable bone cements like SRS into its portfolio to advance regenerative orthopedic solutions. This strategic move underscored a commitment to biomaterials innovation, complementing metal implants with resorbable alternatives that remodel into natural bone over time. By the early , these efforts propelled Synthes to market leadership, with annual revenues surpassing $1 billion and positioning it as a dominant player in orthopedic devices prior to further scale-up.

Acquisition by Johnson & Johnson

, through its DePuy subsidiary, announced a definitive agreement to acquire Synthes on April 27, 2011, in an all-cash transaction valued at approximately $19.7 billion, or CHF 155 per share. The deal aimed to merge Synthes' expertise in trauma and orthopaedics implants with DePuy's existing portfolio, positioning the combined entity as the global leader in surgical tools and implants for bone repair. The acquisition faced regulatory scrutiny, including review, but received U.S. antitrust clearance in June 2012, enabling closure on June 14, 2012. Upon completion, Synthes became a wholly owned , forming with projected combined annual revenues exceeding $7 billion, driven by Synthes' approximately $4 billion in prior-year sales and DePuy's complementary orthopaedics revenue. Strategically, pursued the merger to fortify its orthopaedics segment against intensifying competition from firms like and Zimmer, enhancing product breadth in high-growth areas such as trauma fixation and minimally invasive surgery. For Synthes, the transaction provided expanded access to 's global distribution channels, R&D infrastructure, and manufacturing scale, enabling accelerated innovation without disrupting its core operations. In the immediate post-closing period, integration emphasized unified branding under , with retention of Synthes' headquarters in Oberdorf, , to preserve operational continuity and European market strengths. No large-scale layoffs occurred during this initial phase, as the focus shifted to leveraging synergies in and sales without reported workforce reductions until subsequent years.

Recent Corporate Developments

Following the 2012 acquisition of Synthes by , underwent operational integration into the parent company's MedTech division, focusing on streamlining supply chains, expanding global manufacturing, and advancing product portfolios in orthopedics. From 2012 to 2024, the orthopedics segment achieved steady revenue expansion, reaching $9.2 billion in 2024, driven by procedural volume growth and innovations in implant technologies. During this period, significant investments were directed toward and digital tools, including the VELYS Robotic-Assisted Solution, initially cleared by the FDA in 2021 for total and expanded in 2024 to unicompartmental procedures and spine applications with active and capabilities. On October 14, 2025, announced its intention to separate the orthopedics business through a spinoff, creating an independent, publicly traded entity expected to complete within 18 to 24 months. The standalone company would retain the name and launch with an investment-grade , approximately $9.2 billion in annual revenue, and a comprehensive portfolio spanning hips, knees, trauma, spine, and enabling technologies. This move aligns with J&J's strategy to concentrate on higher-growth areas like innovative MedTech and pharmaceuticals, while granting the orthopedics unit greater autonomy. Analysts anticipate the spinoff will reduce bureaucratic layers inherent in J&J's conglomerate structure, enabling accelerated cycles, enhanced agility in responding to market demands, and improved competitiveness against specialized peers such as and . , which had ceded market leadership in certain segments by late 2024, could leverage its scale—the largest dedicated orthopedics player post-separation—to prioritize targeted innovations, including further VELYS expansions and data-driven surgical solutions. J&J executives cited the separation as a means to unlock value and foster sustained growth exceeding 5% annually for the new entity by 2026.

Products and Technologies

Trauma and Orthopedic Systems

Synthes' trauma and orthopedic systems primarily encompass locking compression plates (LCP), intramedullary nails, and external fixators, engineered to facilitate stable fixation through load-sharing that distribute forces between the implant and bone, promoting healing in fractures such as those in the , , and . The LCP system integrates locking screws with conventional plating via combi-holes, enabling hybrid constructs that enhance angular stability while allowing axial compression, particularly suited for metaphyseal and diaphyseal fractures. Intramedullary nails, such as those in the Advanced Nailing System, serve as the gold standard for diaphyseal fractures, providing intramedullary stabilization with options for and applications to minimize disruption. External fixators, including large and medium modular frames, support temporary stabilization of open or complex fractures, with designs that permit adjustment for correction and load-sharing across pins and bone segments. These systems emphasize mechanical reliability through fixed-angle locking mechanisms that function akin to internal fixators, reducing screw pullout risks in osteoporotic or comminuted bone by creating a rigid implant-bone composite under load. Validation occurs via biomechanical testing, including cadaveric and synthetic bone models, which confirm stability in axial, torsional, and bending loads comparable to or exceeding non-locking alternatives in select configurations. Clinical studies on locking plates show variable union rates, with some reporting higher union (96% vs. 90%) in distal tibia fractures compared to non-locking plates, though others indicate similar or elevated non-union risks (up to 15% higher in certain applications) due to overly rigid constructs impeding callus formation. Intramedullary nailing demonstrates consistent efficacy in fracture management, with low complication rates in proximal femur cases using systems like the TFNA nail. Evolution in these systems has progressed toward variable-angle constructs, expanding from smaller 2.4 mm locking screws for precision applications to broader 3.5-4.5 mm plates that accommodate screw angulation up to 15 degrees, enhancing customization for anatomical fit and fracture-specific trajectories over rigid, one-size-fits-all designs. This adaptability prioritizes surgeon intraoperative flexibility, as evidenced by variable-angle LCP systems for periprosthetic and fractures, validated through showing maintained fixation strength across angles. Overall, these innovations reflect a biomechanical focus on balancing stability with biological healing, though outcomes depend on precise surgical technique to avoid rigidity-related delays in union.

Spine and Neurosurgery Solutions

Synthes advanced and deformity correction through posterior instrumentation systems designed for thoracolumbar stabilization, emphasizing rigid constructs to restore alignment and promote bony union. These solutions addressed conditions such as degenerative , , and trauma-induced instability by enabling multi-level fixation via pedicle screws connected to rods, facilitating load-sharing with the anterior column when combined with interbody support. Prominent products included the Pedicle Screw System, launched in 1994, which employed a top-loading tulip head and mechanism for secure rod capture and segmental correction. Complementing these were interbody fusion devices like the Bullet Lumbar System, indicated for degenerative disc disease at levels T1-L5, providing structural support and space for bone graft placement in anterior or posterior approaches. Integration with biologics, such as autografts or demineralized bone matrix, enhanced fusion rates by delivering osteoinductive factors directly to the graft site. Material innovations focused on and durability, with used for high-strength pedicle screws and polyetheretherketone (PEEK) for radiolucent interbody cages that minimized imaging artifacts. Select implants incorporated porous coatings or structures to improve , as evidenced by biomechanical studies showing porous PEEK yielding higher pullout forces, stiffness, and energy absorption than smooth PEEK or plasma-sprayed coatings. Such designs reduced micromotion at the bone-implant interface, correlating with superior fusion stability in preclinical models. Prior to its 2012 acquisition by , Synthes maintained a leading position in thoracolumbar fixation, powering posterior spinal systems that aligned with AO principles of anatomical reduction and stable fixation to optimize clinical outcomes in fusion procedures.

Craniomaxillofacial and Other Devices

The craniomaxillofacial (CMF) portfolio encompasses implants and instrumentation designed for trauma repair, reconstruction, and orthognathic procedures of the facial skeleton, emphasizing modular systems for precise . Key components include the MatrixMIDFACE™ Plating System, which utilizes plates and screws in sizes ranging from 1.0 mm to 1.5 mm for midface trauma and reconstruction, allowing adaptation to complex fractures via prebent and adaptable plate designs. Similarly, the MatrixORTHOGNATHIC™ System supports in with reversible locking screws and standard fixation options, facilitating segmental movements and stability in mandibular and maxillary advancements. Resorbable fixation options, such as the RAPIDSORB™ Rapid Resorbable Fixation System, provide bioabsorbable plates, screws, and meshes composed of polylactide copolymers, indicated for pediatric craniofacial reconstruction and management where permanent hardware removal is undesirable. These devices resorb over 12-24 months through , minimizing long-term foreign body reactions while supporting osteoconduction, with clinical data indicating low complication rates in pediatric applications comparable to alternatives. For , the CMF Distraction System employs modular, low-profile devices with anti-reversal mechanisms to gradually lengthen mandibular segments, accommodating intraoperative adjustments for conditions like . Patient-specific innovations integrate (CAD/CAM) via the TRUMATCH™ CMF platform, producing 3D-printed plates and anatomical models from preoperative CT scans to achieve submillimeter fit accuracy in complex reconstructions. These custom implants, combined with surgical guides, enable precise transfer of virtual plans to the operating room, reducing intraoperative contouring needs and operative times by up to 30% in reported CMF cases relative to off-the-shelf alternatives. Such technologies enhance outcomes in tumor resections and severe trauma by minimizing revision rates through improved anatomic restoration.

Controversies and Regulatory Issues

Norian XR Bone Cement Incident

Norian XR, an injectable bone cement manufactured by Synthes, received FDA 510(k) clearance in March 2003 specifically for filling voids and gaps in bone in the extremities, such as those created by trauma or , where the voids were not intrinsic to the stability of the bony structure. The product's labeling explicitly warned against use in high-pressure environments or for treating conditions involving vascular structures, due to risks of unintended migration and hardening in vasculature. Despite these limitations, Synthes internal documents and communications from 2002 onward indicated exploratory promotion to orthopedic surgeons for off-label application in vertebroplasty and kyphoplasty procedures to treat vertebral compression fractures, primarily in elderly patients with . Between 2002 and 2004, Synthes facilitated unauthorized human use of XR in spinal augmentation on approximately 200 patients, often high-risk individuals with comorbidities, without conducting required preclinical animal safety studies or obtaining investigational device exemption (IDE) approval from the FDA. This off-label experimentation resulted in at least five documented cases of symptomatic directly attributed to leakage into paravertebral veins during injection, with the material traveling to the lungs and hardening there, occluding pulmonary arteries. Autopsy findings in fatal cases confirmed cement fragments in the pulmonary vasculature and right heart, contributing to acute and cardiovascular collapse, particularly lethal in patients with pre-existing pulmonary or cardiac vulnerabilities. The incident's causality stemmed from the material's biophysical properties: Norian XR is a low-viscosity paste that hardens via a with body fluids within minutes, intended for low- cavity filling, but under the elevated injection pressures of vertebroplasty (often exceeding venous pressure), it could extravasate through cancellous into adjacent low-pressure venous plexuses. Preceding , including canine models, had demonstrated rapid acceleration and fatal when the entered the bloodstream, yet these risks were disregarded in applications despite label contraindications. Empirical outcomes highlighted the procedure's inherent hazards in the thoracic spine, where venous drainage directly connects to the lungs, amplifying the potential for systemic migration compared to extremity uses. By November 2004, the FDA issued a warning letter to Synthes citing these adverse events and demanding cessation of unapproved spinal promotions. In June 2009, the U.S. Department of Justice (DOJ) indicted Synthes Inc., its subsidiary Corporation, and four executives—Michael D. Huggins, Thomas B. Higgins, Richard E. Bohner, and John J. Walsh—on charges related to the promotion and distribution of XR for unapproved uses in vertebral compression fractures. faced 52 felony counts, including to defraud the United States and conduct unauthorized human clinical trials, while Synthes was charged with 44 counts of shipping adulterated and misbranded medical devices in interstate commerce; the executives faced charges for shipping violations and related . These actions followed FDA warnings dating back to 2002 prohibiting such off-label promotion and clinical testing without investigational device exemptions or approvals. In October 2010, Synthes and entered guilty pleas as part of a agreement with the DOJ, with Norian admitting to one count of and one count of shipping adulterated devices, and Synthes pleading guilty to a single count of shipping misbranded devices. The companies agreed to pay a combined $23 million in penalties, including a $22.5 million criminal fine and forfeiture of assets tied to the violations, without admitting intent to cause harm, as the offenses were in nature for the shipping charges. The executives also pleaded guilty to shipping offenses; sentencing in 2011 and 2012 resulted in prison terms ranging from six to 18 months for Huggins (18 months), Higgins (12 months), Bohner (six months), and Walsh (six months), plus fines of $100,000 each, despite the lack of intent elements in the core charges. As required by the plea agreement to avoid further penalties or exclusion from federal healthcare programs, Synthes divested Corporation's assets in May 2011 to Kensey Nash Corporation for $22 million in cash, including the Norian product lines and manufacturing facility. No systemic of Norian XR was mandated by regulators, though its use for the implicated indications remained unapproved. Subsequent civil lawsuits from affected patients' families continued into the ; for instance, in a 2016 Washington state trial over a patient's death, Synthes reached a confidential settlement with the family during proceedings, while a attributed no liability to the surgeon or hospital and only minor responsibility (5%) to Synthes in pretrial allocations, amid claims seeking up to $6 million. These resolutions highlighted enforcement focused on promotional violations rather than broader product safety overhauls, with total penalties representing a fraction of Synthes' revenues prior to its 2012 acquisition by .

Impact and Legacy

Contributions to Surgical Advancements

Synthes advanced by commercializing and promoting techniques grounded in the AO Foundation's principles, which emphasize anatomical reduction of fractures, stable mechanical fixation, preservation of vascularity, and early to optimize . These methods marked a shift from conservative casting and traction to operative intervention, enabling faster recovery and functional restoration in trauma cases. The principles have been integrated into global surgical standards, with the AO network influencing over 215,000 healthcare professionals and facilitating standardized care that improves long-term outcomes. Empirical data link AO-guided internal fixation to reduced complication rates, including lower incidences of surgical site infections and nonunion compared to non-operative or less stable methods, as stable constructs minimize soft tissue disruption and promote primary bone healing. Biomechanical stability, a core AO tenet validated through extensive research, correlates with higher union rates and fewer revision surgeries, underpinning evidence-based protocols that prioritize load-sharing implants over rigid over-stabilization. Post-2012 integration into expanded these impacts via technologies like -based systems, which enhance precision in complex procedures such as spine instrumentation while cutting radiation exposure—a key gain given cumulative risks to staff and . -assisted techniques reduce dose per pedicle from 6.0 × 10^{-3} mSv to 1.8 × 10^{-3} mSv (a 70% decrease) and exposure proportionally, shortening time without compromising accuracy. This legacy of data-driven innovation continues to lower operative risks and costs by minimizing revisions and radiation-related monitoring needs.

Criticisms and Lessons Learned

Critics have faulted Synthes for prioritizing rapid market expansion over , particularly in the promotion of Norian XR for unapproved spinal applications, which bypassed required Investigational Device Exemption (IDE) processes and contributed to at least four intraoperative deaths from caused by cement leakage. This off-label advocacy, despite explicit FDA labeling warnings against load-bearing spinal use, exemplified broader industry tendencies where physicians employ devices off-label in a substantial fraction of cases—estimated at up to 60% for certain implants like drug-eluting stents—yet manufacturer promotion without safety data amplifies risks absent empirical validation. Synthes' internal culture, driven by aggressive growth under leadership including Chairman Hansjoerg Wyss, fostered compliance shortcuts, as evidenced by unauthorized "training" sessions functioning as trials on approximately 200 patients, ignoring preclinical warnings about the cement's potential to accelerate clot formation upon . However, the company's 2010 guilty plea to one count of to impede FDA functions and 110 counts for misbranded shipments, coupled with a $23.1 million fine and divestiture of Norian without broader corporate dissolution, indicates lapses stemming from overzealous innovation pursuits rather than intentional deceit, as upper management accepted responsibility through agreements. Key lessons from the incident underscore the necessity for enhanced preclinical modeling of injectable biomaterials' and embolization risks prior to human application, prompting FDA reinforcements on IDE mandates for high-risk adaptations. Post-2012, the sector adopted stricter adverse event surveillance and compliance training protocols, balancing patient safeguards with R&D incentives by permitting physician-directed while curtailing promotional overreach, thereby mitigating recurrence without unduly impeding iterative advancements in orthopedic technologies.

References

  1. https://www.forbes.com/companies/synthes/
  2. https://www.medicaldevice-network.com/features/timeline-charting-the-history-of-orthopaedic-devices-as-depuy-synthes-turns-125/
  3. https://www.jnj.com/our-heritage/timeline
  4. https://www.jnj.com/media-center/press-releases/johnson-johnson-and-synthes-announce-definitive-merger-agreement-to-create-worlds-most-innovative-and-comprehensive-orthopaedics-business
  5. https://www.nytimes.com/2009/06/17/business/17device.html
  6. https://www.cbsnews.com/news/bone-cement-company-norian-accused-of-experimenting-on-humans/
  7. https://www.fiercebiotech.com/medical-devices/former-synthes-execs-blacklisted-over-bone-cement-scandal
  8. https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-intent-to-separate-its-orthopaedics-business
  9. https://www.aofoundation.org/who-we-are/about-ao/ao-archive-and-history
  10. https://www.aofoundation.org/what-we-do/innovation-translation/ao-technical-commission/ao-technical-commission-history
  11. https://link.springer.com/book/10.1007/978-3-642-96065-9
  12. https://ryortho.com/2012/07/how-jnj-bought-synthes-and-how-it-almost-didnrsquot-happen-part-i/
  13. https://voiceofsandiego.org/wp-content/uploads/app/pdf/bioreport2051909.pdf
  14. https://thepenngazette.com/alumni-notes-83/
  15. https://www.jnjmedtech.com/en-US/product/modular-foot-system
  16. https://www.jnjmedtech.com/en-US/product/modular-hand-system
  17. https://ryortho.com/2011/06/final-norian-chapter-unfolds/
  18. https://rroeder.nd.edu/assets/387886/fortunesynthes.pdf
  19. https://fortune.com/2012/09/18/bad-to-the-bone-a-medical-horror-story/
  20. https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-2012-second-quarter-results
  21. https://www.nytimes.com/2011/04/28/business/28drug.html
  22. https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-us-regulatory-clearance-for-synthes-acquisition-closing-date-for-transaction-set
  23. https://www.sec.gov/Archives/edgar/data/200406/000095012311093402/y91766b3e424b3.htm
  24. https://www.odtmag.com/breaking-news/jnjs-2012-revenue-shows-strong-growth-in-orth/
  25. https://www.reuters.com/article/world/jj-to-buy-synthes-for-216-billion-idUSTRE73Q0WC/
  26. https://www.reuters.com/legal/litigation/jj-spin-off-orthopedics-business-raises-full-year-forecast-2025-10-14/
  27. https://www.fiercebiotech.com/medtech/jj-spinning-orthopedics-unit-all-about-shrinking-grow-faster
  28. https://www.jnj.com/media-center/press-releases/depuy-synthes-receives-510k-fda-clearance-of-the-velys-robotic-assisted-solution-for-use-in-unicompartmental-knee-arthroplasty-procedures
  29. https://www.jnj.com/media-center/press-releases/depuy-synthes-launches-its-first-active-spine-robotics-and-navigation-platform
  30. https://www.wsj.com/health/healthcare/johnson-johnson-to-split-off-orthopedics-business-2b9f3d62
  31. https://www.medtechdive.com/news/jnj-ortho-spinoff-industry-impact/802983/
  32. https://www.orthoworld.com/can-jnj-spin-of-depuy-synthes-revive-business/
  33. https://www.stockspinoffs.com/2025/10/22/jnj-depuy-synthes-spinoff/
  34. https://www.bnnbloomberg.ca/business/2025/10/14/jj-to-spin-off-orthopedics-business-sees-2026-sales-growth-of-over-5/
  35. https://www.jnjmedtech.com/en-US/product/locking-compression-plate-system
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC8567815/
  37. https://www.jnjmedtech.com/en-US/product/large-external-fixation-system
  38. https://www.rch.org.au/uploadedFiles/Main/Content/ortho/LCP_Large_Fragment.pdf
  39. https://www.jnjmedtech.com/en-US/product/advanced-nailing-system
  40. https://www.jnjmedtech.com/en-EMEA/product/large-and-medium-external-fixation-system
  41. https://upload.orthobullets.com/journalclub/free_pdf/15475843.pdf
  42. https://www.jnjmedtech.com/system/files/pdf/ANS_System%2520Brochure_133807-200302.pdf
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC3626209/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC9449446/
  45. https://www.ijmedph.org/Uploads/Volume15Issue3/226.%25202741.%2520IJMEDPH_Arpita_1222-1227.pdf
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC11845636/
  47. https://www.sciencedirect.com/science/article/abs/pii/S0020138319305819
  48. https://e-jmt.org/journal/view.php?doi=10.12671/jkfs.2020.33.4.189
  49. https://www.researchgate.net/publication/272186776_Concept_of_variable_angle_locking-evolution_and_mechanical_evaluation_of_a_recent_technology_THE_CONCEPT_OF_VARIABLE_ANGLE_LOCKING
  50. https://www.jnjmedtech.com/system/files/pdf/7568_090555-190702%2520DSUSEM_BuildingonSuccessBrochure_Proof_0.pdf
  51. https://orthospinenews.com/2021/06/09/depuy-synthes-launches-2-7-mm-variable-angle-locking-compression-plate-clavicle-system-designed-to-accommodate-different-shapes-and-sizes-of-the-collarbone/
  52. https://www.jnjmedtech.com/en-US/specialty/trauma-and-extremities?pmid=c0a80237f047bbcafc766e524735e9a9&searchData=Search%252520DePuy%252520Synthes&page=7
  53. https://int.aofoundation.org/innovations/-/media/project/aocd/innovations/editorial/2021-01-ao-itc-innovations_2.pdf
  54. https://josr-online.biomedcentral.com/articles/10.1186/s13018-024-04700-4
  55. https://www.sciencedirect.com/science/article/pii/S1877056818302299
  56. https://www.jnjmedtech.com/en-US/specialty/spine
  57. https://neurospineproductreview.com/moss-miami-pedicle-screw-system
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC6966429/
  59. https://pubmed.ncbi.nlm.nih.gov/30236838/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC6211303/
  61. https://thespinemarketgroup.com/wp-content/uploads/2020/07/Expedium-5.5.Family-Catalogue-DepuySynthes.pdf
  62. https://www.jnjmedtech.com/en-US/specialty/craniomaxillofacial-cmf
  63. https://www.jnjmedtech.com/en-US/product/matrixmidface-plating-system
  64. https://www.jnjmedtech.com/en-US/product/matrixorthognathic-system
  65. https://www.jnjmedtech.com/en-US/product/rapidsorb-rapid-resorbable-fixation-system
  66. https://pdf.medicalexpo.com/pdf/depuy-synthes/rapidsorb-rapid-resorbable-fixation-system/79814-226701.html
  67. https://www.jnjmedtech.com/en-US/product/cmf-distractors
  68. https://www.jnjmedtech.com/en-US/product/trumatch-cmf-titanium-3d-printed-plates-and-implants
  69. https://www.jnjmedtech.com/en-US/specialty/cmf/trumatch-cmf-personalized-solutions
  70. http://www.diva-portal.org/smash/get/diva2:1291652/FULLTEXT01.pdf
  71. http://www.circare.org/fdawls2/synthes_20041105.pdf
  72. https://www.justice.gov/archive/usao/pae/News/2010/Oct/synthes_supersedinginformation.pdf
  73. https://www.mddionline.com/business/digging-into-the-numbers-behind-the-synthes-norian-debacle
  74. https://www.minnpost.com/second-opinion/2012/09/fortune-tells-chilling-deadly-tale-companys-end-run-around-fda-rules/
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC3528895/
  76. https://www.justice.gov/archive/usao/pae/News/2009/jun/synthesind.pdf
  77. https://ryortho.com/2009/06/inside-the-synthes-indictment/
  78. https://www.justice.gov/archive/usao/pae/News/2010/Oct/synthes%2Cnorian_release.pdf
  79. https://www.modernhealthcare.com/article/20101004/NEWS/310049941/norian-will-plead-guilty-to-felony-pay-22-5-million-penalty/
  80. https://www.lexology.com/library/detail.aspx?g=a44359e4-8495-41dc-a2bc-8f32aed875f0
  81. https://www.inquirer.com/philly/business/20110525_rd_Synthes_sells_Norian_to_Kensey_Nash.html
  82. https://www.massdevice.com/synthes-settles-doc-hospital-cleared-norian-xr-bone-cement-suit/
  83. https://www.massdevice.com/feds-force-synthes-sell-norian-pay-23-million-fines/
  84. https://www.sciencedirect.com/science/article/pii/S0020138319304152
  85. https://www.researchgate.net/publication/10727941_AO_philosophy_and_principles_of_fracture_management_-_Its_evolution_and_evaluation
  86. https://www.researchgate.net/publication/342486276_The_Influence_of_Biomechanical_Stability_on_Bone_Healing_and_Fracture-Related_Infection_The_Legacy_of_Stephan_Perren
  87. https://www.thespinejournalonline.com/article/S1529-9430%2819%2930122-6/abstract
  88. https://ryortho.com/2016/11/depuy-synthes-slashes-or-radiation-with-new-mis-navigation/
  89. https://www.jacc.org/doi/10.1016/j.jacbts.2022.12.012
  90. https://apnews.com/general-news-8b4a0395715a4e60879f1167557f2a44
  91. https://www.healio.com/news/orthopedics/20120331/former-synthes-executives-sentenced-to-prison-for-unauthorized-bone-cement-trials
  92. https://www.fda.gov/media/173172/download
  93. https://www.fda.gov/media/184871/download
Add your contribution
Related Hubs
User Avatar
No comments yet.